Article Correctness Is Author's Responsibility: In the Lab and in the Clinic, Alisertib with TAK-228 Excels Against Solid Tumors, Including Triple-Negative ****** Cancer

Two University of Colorado Cancer Center studies presented this weekend at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting show that using the drug alisertib along with the drug TAK-228 is more effective against triple-negative ****** …

read more